SCHEMBL4869965

SCHEMBL4869965

COc1ccc2c(c1)CCCCN2C(=O)Nc1ccc(O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.64
PDK1 Q15118 1/20 0.59
PDK2 Q15119 1/20 0.59
PDK3 Q15120 1/20 0.59
PDK4 Q16654 1/20 0.59
HSD17B10 Q99714 1/20 0.59
L3MBTL1 Q9Y468 2/20 0.57
ALDH1A1 P00352 2/20 0.57
MAPK1 P28482 1/20 0.57
LMNA P02545 2/20 0.57
TP53 P04637 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
NPC1 O15118 1/20 0.57
PKM P14618 1/20 0.57
NFKB1 P19838 1/20 0.57
MAOB P27338 1/20 0.57
RAB9A P51151 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
THRB P10828 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4863193 0.91 MAPT (0.64) MAPTPDK1PDK2PDK3PDK4
SCHEMBL4862236 0.91 MAPT (0.64) MAPTL3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL4869061 0.90 MAPT (0.63) MAPTPDK1PDK2PDK3PDK4
SCHEMBL4869626 0.89 MAPT (0.69) MAPTHSD17B10L3MBTL1ALDH1A1MAPK1
SCHEMBL4870695 0.88 MAPT (0.52) MAPTPDK1PDK2PDK3PDK4
SCHEMBL4867127 0.87 MAPT (0.56) MAPTPDK1PDK2PDK3PDK4
SCHEMBL4870691 0.87 PDK1 (0.58) MAPTPDK1PDK2PDK3PDK4
SCHEMBL4865371 0.86 MAPT (0.58) MAPTHSD17B10L3MBTL1ALDH1A1MAPK1
SCHEMBL4867152 0.86 TP53 (0.64) MAPTPDK1PDK2PDK3PDK4
SCHEMBL4860848 0.85 MAPT (0.61) MAPTPDK1PDK2PDK3PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 MAPT 3398/4885PDK1 2625/4885PDK2 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.